# My antiviral left the formulary: can I just stop? Do not stop abruptly when coverage changes: the risks of withdrawal, what to assess before switching, and how to bridge a gap and monitor afterwards. - URL: https://openhbv.com/articles/my-antiviral-left-the-formulary-can-i-just-stop?locale=en - Language: en - Translation key: antiviral-drug-coverage-switch - Review status: source_backed - Last reviewed: 2026-11-05 - Audience: Patients and families - Region: Global - Tags: Treatment, Monitoring ## Do not stop first: abrupt withdrawal is risky When a letter says your medicine is no longer covered or will be self-paid, the easiest reaction is to stop for a few days and see. For people treated for chronic hepatitis B, stopping suddenly can cause HBV DNA rebound and a hepatitis flare, which is especially dangerous with cirrhosis. Until an alternative is arranged, keep taking the medicine exactly as prescribed and contact the prescriber or pharmacist promptly. If a gap is unavoidable, tell the clinician the exact date so a bridging plan and monitoring can be arranged. ## Why a drug leaves the formulary Formularies, insurance coverage, and hospital procurement change regularly. A brand may be replaced by a generic, or removed after price negotiations fail. Coverage differs by insurer, region, and hospital, so a medicine covered for someone else may not be covered for you. These changes are usually not a medical judgment about your case. Do not conclude that your treatment has failed just because the drug left the list. ## What to ask before switching Switching is not just changing a name. The clinician needs your kidney function, bone risk, pregnancy plans, prior medicines and resistance history, HBV DNA control, and cirrhosis status to choose the alternative. If you take tenofovir alafenamide (TAF), options usually include tenofovir disoproxil fumarate (TDF) or entecavir, and the same is true in reverse. Each differs in kidney, bone, pregnancy, and drug-interaction considerations, so price should not be the only factor. ## Understanding TAF, TDF, and entecavir These are all common first-line oral antivirals. TDF has been used for a long time and is often cheaper, but needs more attention to kidney function and bone density. TAF has better kidney and bone data, but price and access vary by region. Entecavir is another common choice. A clinician decides which fits you. "Is a generic worse?" is a common question. An approved generic has the same active ingredient as the original brand; what matters is the manufacturer, formulation, and your tolerance. After switching, follow-up testing confirms that viral control has not changed. ## If you must pay out of pocket or face a gap Ask the hospital pharmacy, insurance office, or manufacturer patient-assistance programme about bridging supply, charity programmes, or generic options. Also ask the clinician whether an equivalent alternative can be prescribed with an adjusted follow-up plan. Do not reduce the dose, skip days, or mix medicines to save money; that can weaken viral control. If a short self-paid bridge is needed, confirm with the clinician which extra tests to do during that period. ## Monitoring after a switch After switching, HBV DNA and ALT/AST are usually rechecked, with kidney function, phosphate, urinalysis, and bone density when relevant. People with cirrhosis continue liver cancer surveillance. The clinician sets the timing based on why you switched and your risk. If fatigue worsens, jaundice appears, urine darkens, the abdomen swells, or fever develops after a switch, contact the clinic promptly instead of waiting for the next visit. ## Questions to ask at your visit 1. Why is my medicine off the formulary: price, procurement, or policy? 2. Which alternatives can I switch to, and do my kidneys, bones, or pregnancy plans affect the choice? 3. When should HBV DNA and liver tests be rechecked after the switch? 4. Are there patient-assistance, bridging-supply, or generic options? 5. If I run out for a few days, what should I do and when should I contact you? 6. Do I still need liver cancer surveillance or other tests? ## Action checklist After a coverage change, keep taking your medicine as prescribed and do not stop on your own. Contact the prescriber or pharmacist promptly with the date you would run out. Ask about alternatives and the monitoring plan. Look for bridging supply through the pharmacy, insurer, or assistance programmes. After switching, complete HBV DNA, ALT, and kidney checks on schedule. Seek care promptly for jaundice, dark urine, abdominal swelling, or marked fatigue. ## References - [Hepatitis B Online Choosing an Initial HBV Treatment Regimen](https://openhbv.com/sources/hepatitis-b-online-choosing-an-initial-hbv-treatment-regimen.md?locale=en) — University of Washington Hepatitis B Online - Original: https://www.hepatitisb.uw.edu/go/hbv/medications-used-to-treat-hbv - Section: First-line medicines and selection - Note: Hepatitis B Online treatment material covers entecavir, TDF, and TAF first-line options and the role of kidney function, bone risk, and comorbidities. - Quote: - Accessed: 2026-11-05 - [WHO 2024 Chronic Hepatitis B Guidelines](https://openhbv.com/sources/who-2024-chronic-hepatitis-b-guidelines.md?locale=en) — World Health Organization - Original: https://www.who.int/publications/i/item/9789240090903 - Section: Treatment and long-term management - Note: WHO 2024 chronic hepatitis B guidance notes most people need long-term treatment and sets out medicine selection and monitoring principles. - Quote: - Accessed: 2026-11-05 - [AASLD Hepatitis B Guidance](https://openhbv.com/sources/aasld-hepatitis-b-guidance.md?locale=en) — American Association for the Study of Liver Diseases - Original: https://www.aasld.org/ - Section: Adjusting treatment and follow-up - Note: AASLD guidance bases treatment changes on viral control, liver tests, and comorbidities rather than a single factor. - Quote: - Accessed: 2026-11-05 - [Hepatitis B Online Monitoring Persons On and Off HBV Therapy](https://openhbv.com/sources/hepatitis-b-online-monitoring-persons-on-and-off-hbv-therapy.md?locale=en) — University of Washington Hepatitis B Online - Original: https://www.hepatitisb.uw.edu/go/hbv/monitoring-persons-on-hbv-therapy - Section: Monitoring on treatment - Note: Hepatitis B Online monitoring material covers HBV DNA, ALT, and kidney monitoring during treatment. - Quote: - Accessed: 2026-11-05 This tool is for health education only and does not provide a personal diagnosis or treatment advice. Please consult a qualified doctor for individual medical decisions.